New Delhi: Suven Life Sciences has been granted a patent each by China, Eurasia and Hong Kong for a drug used in the treatment of neuro-degenerative diseases.
The company has been granted “one product patent from China, one product patent from Eurasia and one product patent from Hong Kong corresponding to the New Chemical Entities (NCEs) for the treatment of disorders associated with Neuro-degenerative diseases”, it said in a BSE filing.
The patents will be valid till 2032.
“We are very pleased by the grant of these patents to Suven for our pipeline of molecules in the CNS (central nervous system) arena, which are being developed for cognitive disorders with high unmet medical need with a huge market potential globally,” Suven Life CEO Venkat Jasti said.
With these new patents, Suven has 20 granted patents from China, 16 from Eurasia and 19 from Hong Kong.
“These granted patents are exclusive intellectual property of Suven and are achieved through internal discovery research efforts. Products out of these inventions may be out-licensed at various phases of clinical development like phase-I or phase-II,” Suven said.
Suven Life Sciences stock was trading 2.39 per cent higher at Rs 205.60 on BSE.